Design Therapeutics, Inc.
DSGN
$14.83
$0.443.06%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -11.51% | -24.05% | -40.74% | -41.16% | -25.65% |
| Total Depreciation and Amortization | 0.98% | 1.31% | 4.36% | 5.13% | 7.73% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 39.72% | 65.52% | 70.09% | 88.35% | 72.63% |
| Change in Net Operating Assets | -38.25% | 766.95% | 413.19% | 181.93% | 138.61% |
| Cash from Operations | -8.78% | -13.79% | -26.11% | -13.49% | 0.77% |
| Capital Expenditure | 61.54% | 44.24% | 43.24% | 56.68% | 67.20% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -89.85% | -75.90% | -47.84% | -24.06% | -65.13% |
| Cash from Investing | -90.02% | -76.12% | -47.87% | -23.81% | -65.11% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 6,982.25% | 8,746.71% | 4,917.15% | -8.92% | -15.07% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 6,982.25% | 8,746.71% | 4,917.15% | -8.92% | -15.07% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 73.86% | 94.30% | -518.71% | -738.73% | -240.50% |